-
-
-
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2025-09-19
SHANGHAI, China & JERSEY CITY, NJ – SEPTEMBER 19, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.
-
-
-
-
Fosun International Achieves AA- in HSI ESG Rating for Third Consecutive Year, Marks Sixth Year as Constituent of Hang Seng Corporate Sustainability Benchmark Index
2025-09-14
On 9 September 2025, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International” or the “Company”) was informed that in the 2025 Sustainability Ratings of listed companies released by Hang Seng Indexes Company, Fosun International received an AA- rating for the third consecutive year.
-
-
-
-
Xu Xiaoliang: “Combining Global Resources with China’s Capabilities”, Forging a New Future with Globalization and Innovation
2025-09-13
Centering its strategic focus on “business streamlining, adopting an asset-light strategy and collaborating with key partners, achieving balanced investment and divestment”, Fosun International (00656.HK) has sustained steady business development amid a complex global environment.
-
-
-
-
Chen Qiyu: Fosun’s global strategy and innovation sustain strong momentum
2025-09-12
On September 11, The Asset, a leading financial magazine in the Asia-Pacific region, published an exclusive interview with Chen Qiyu, Co-CEO of Fosun International. The article highlighted Fosun’s performance in its 2025 interim results, as well as the company’s ongoing progress in global expansion and innovation-driven development.
-
-
-
-
Fosun International Holds Signing Ceremony for USD910 Million Equivalent Syndicated Loan, Underscoring Global Market Confidence in its Future Development
2025-09-10
On 9 September 2025, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International”, “Fosun”, or the “Company”) held the signing ceremony for its 2025 three-year sustainability-linked syndicated loan in Hong Kong.
-
-
-
-
Fosun International Recognized among Fortune’s 2025 “Most Admired Chinese Companies” List
2025-09-10
On 9 September, Fortune China magazine released its 2025 list of “Most Admired Chinese Companies”, in which Fosun International Limited (“Fosun International” or the “Company”) (HKEX stock code: 00656) was included in the Industry Star List.
-
-
-
-
U.S. FDA Clearance of IND for Pembrolizumab Biosimilar HLX17
2025-09-09
Shanghai, China, September 8, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced the investigational new drug (IND) application for its HLX17, a proposed pembrolizumab biosimilar independently developed by the company, was approved by the U.S. Food and Drug Administration (FDA) as an adjuvant therapy for certain resected solid tumors,
-
-
-
-
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2025-09-02
SHANGHAI, China & JERSEY CITY, NJ – September 2, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.
-
-
-
-
Lanvin Group Reports H1 2025 Revenue of €133 Million Operational Discipline and Early Recovery Momentum Set Foundation for Growth in H2
2025-08-30
August 29, 2025 -- Lanvin Group (NYSE: LANV, the "Group"), a global luxury fashion group with Lanvin, Wolford, Sergio Rossi, St. John and Caruso in its portfolio of brands, today announced its unaudited results for the first half of 2025. Despite ongoing industry-wide pressures, the Group delivered performance underpinned by strong cost discipline, operational efficiency, and visible signs of recovery in the second quarter.
-